PRAME and acute myeloid leukemia: TCR-T cells targeting tumor-associated antigens (TAAs), such as WT1, PRAME, and HA-1, exert anti-leukemic effects in vitro and in clinical studies with high-risk AML patients post-HSCT [9–12].